In vivo synergistic antitumor effect and safety of siRNA and lonidamine dual-loaded hierarchical targeted nanoparticles

International Journal of Pharmaceutics

Volumn 506, Issue 1-2, 2016, Pages 207-213

  Zhang, Bing Feng ^a,b   Xing, Lei ^a   Qiao, Jian Bin ^a   Cui, Peng Fei ^a   Wang, Feng Zhen ^a   Zhang, Jia Liang ^a   Xu, Cheng Xiong ^c   Jiang, Hu Lin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b YICHUN UNIVERSITY   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cancer combination therapy; Co delivery; Hierarchical targeted nanoparticles; In vivo anti tumor; Lonidamine; siRNA

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EOSIN; HEMATOXYLIN; LONIDAMINE; NANOCARRIER; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; DRUG CARRIER; INDAZOLE DERIVATIVE; NANOPARTICLE; POLYMER;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOCOMPATIBILITY; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SAFETY; HIERARCHICAL TARGETED DELIVERY SYSTEM; HISTOLOGY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; TUNEL ASSAY; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DRUG SCREENING; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; IN SITU NICK-END LABELING; INDAZOLES; MALE; MICE; MICE, INBRED ICR; NANOPARTICLES; POLYMERS; RNA, SMALL INTERFERING; SARCOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964503274     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2016.04.056     Document Type: Article

References (29)

1. N. Cao, D. Cheng, S. Zou, H. Ai, J. Gao, and X. Shuai The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells Biomaterials 32 2011 2222 2232
2. A.M. Chen, M. Zhang, D. Wei, D. Stueber, O. Taratula, T. Minko, and H. He Co-delivery of Doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells Small 5 2009 2673 2677
3. Y. Chen, J.J. Wu, and L. Huang Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy Mol. Ther. 18 2010 828 834
4. Y. Chen, W. Zhang, Y. Huang, F. Gao, X. Sha, K. Lou, and X. Fang The therapeutic effect of methotrexate-conjugated Pluronic-based polymeric micelles on the folate receptor-rich tumors treatment Int. J. Nanomed. 10 2015 4043 4057
5. Z.J. Deng, S.W. Morton, E. Ben-Akiva, E.C. Dreaden, K.E. Shopsowitz, and P.T. Hammond Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment ACS Nano 7 2013 9571 9584
6. D. Ding, J. Liu, G. Feng, K. Li, Y. Hu, and B. Liu Bright far-red/near-infrared conjugated polymer nanoparticles for in vivo boimaging Small 9 2013 3093 3102
7. N.S. Gandhi, R.K. Tekade, and M.B. Chougule Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances J. Controlled Release 194 2014 238 256
8. M. Han, Q. Lv, X.-J. Tang, Y.-L. Hu, D.-H. Xu, F.-Z. Li, W.-Q. Liang, and J.-Q. Gao Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex J. Controlled Release 163 2012 136 144
9. S.-H. Hong, J.-E. Kim, Y.-K. Kim, A. Minai-Tehrani, J.-Y. Shin, B. Kang, H.-J. Kim, C.-S. Cho, C. Chae, and H.-L. Jiang Suppression of lung cancer progression by biocompatible glycerol triacrylate-spermine-mediated delivery of shAkt1 Int. J. Nanomed. 7 2012 2293 2306
10. C.-M.J. Hu, and L. Zhang Nanoparticle-based combination therapy toward overcoming drug resistance in cancer Biochem. Pharmacol. 83 2012 1104 1111
11. S.H. Kang, H.-J. Cho, G. Shim, S. Lee, S.-H. Kim, H.-G. Choi, C.-W. Kim, and Y.-K. Oh Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy Pharm. Res. 28 2011 3069 3078
12. D. Lane Designer combination therapy for cancer Nat. Biotechnol. 24 2006 163 164
13. Y.-C. Lee, C.-H. Lee, H.-P. Tsai, H.-W. An, C.-M. Lee, J.-C. Wu, C.-S. Chen, S.-H. Huang, J. Hwang, and K.-T. Cheng Targeting of topoisomerase I for prognoses and therapeutics of Camptothecin-resistant ovarian cancer PLoS One 10 2015 e0132579
14. Y. Li, R. Liu, J. Yang, G. Ma, Z. Zhang, and X. Zhang Dual sensitive and temporally controlled camptothecin prodrug liposomes codelivery of siRNA for high efficiency tumor therapy Biomaterials 35 2014 9731 9745
15. T. Lu, J. Sun, X. Chen, P. Zhang, and X. Jing Folate-conjugated micelles and their folate-receptor-mediated endocytosis Macromol. Biosci. 9 2009 1059 1068
16. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer. Res. 46 1986 6387 6392
17. H. Meng, M. Liong, T. Xia, Z. Li, Z. Ji, J.I. Zink, and A.E. Nel Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line ACS Nano 4 2010 4539 4550
18. L. Milane, Z. Duan, and M. Amiji Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer PLoS One 6 2011 e24075
19. G. Myhr, and J. Moan Synergistic and tumour selective effects of chemotherapy and ultrasound treatment Cancer Lett. 232 2006 206 213
20. G.S. Price, R.L. Page, J.E. Riviere, J.M. Cline, and D. Thrall Pharmacokinetics and toxicity of oral and intravenous lonidamine in dogs Cancer Chemother. Pharmacol. 38 1996 129 135
21. T.-M. Sun, J.-Z. Du, Y.-D. Yao, C.-Q. Mao, S. Dou, S.-Y. Huang, P.-Z. Zhang, K.W. Leong, E.-W. Song, and J. Wang Simultaneous delivery of siRNA and paclitaxel via a two-in-one micelleplex promotes synergistic tumor suppression ACS Nano 5 2011 1483 1494
22. W. Wang, M. Xi, X. Duan, Y. Wang, and F. Kong Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo Int. J. Nanomed. 10 2015 3737 3750
23. X. Xu, K. Xie, X.-Q. Zhang, E.M. Pridgen, G.Y. Park, D.S. Cui, J. Shi, J. Wu, P.W. Kantoff, and S.J. Lippard Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug Proc. Natl. Acad. Sci. U. S. A. 110 2013 18638 18643
24. X. Xue, and X.-J. Liang Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology Chin. J. Cancer 31 2012 100 109
25. H.-C. Yen, H. Cabral, P. Mi, K. Toh, Y. Matsumoto, X. Liu, H. Koori, A. Kim, K. Miyazaki, and Y. Miura Light-induced cytosolic activation of reduction-sensitive camptothecin-loaded polymeric micelles for spatiotemporally controlled in vivo chemotherapy ACS Nano 8 2014 11591 11602
26. B.-F. Zhang, L. Xing, P.-F. Cui, F.-Z. Wang, R.-L. Xie, J.-L. Zhang, M. Zhang, Y.-J. He, J.-Y. Lyu, and J.-B. Qiao Mitochondria apoptosis pathway synergistically activated by hierarchical targeted nanoparticles co-delivering siRNA and lonidamine Biomaterials 61 2015 178 189
27. X. Zhao, F. Li, Y. Li, H. Wang, H. Ren, J. Chen, G. Nie, and J. Hao Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer Biomaterials 46 2015 13 25
28. C. Zheng, M. Zheng, P. Gong, J. Deng, H. Yi, P. Zhang, Y. Zhang, P. Liu, Y. Ma, and L. Cai Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy Biomaterials 34 2013 3431 3438
29. C. Zhu, S. Jung, S. Luo, F. Meng, X. Zhu, T.G. Park, and Z. Zhong Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers Biomaterials 31 2010 2408 2416